ParkinsonCanadaV1, Ncbi, Merge, bibRecord, 000260

New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

Identifieur interne : 000260 ( Ncbi/Merge ); précédent : 000259; suivant : 000261

New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

Auteurs : A. Hadj Tahar [Canada] ; R. Grondin ; L. Grégoire ; F. Calon ; T. Di Paolo ; P J Bédard

Source :

Advances in neurology [ 0091-3952 ] ; 2003.

RBID : pubmed:12442663

English descriptors

KwdEn :
- Animals, Brain (drug effects), Brain (metabolism), Brain (physiopathology), Disease Models, Animal, Dopamine (metabolism), Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (physiopathology), Dyskinesia, Drug-Induced (prevention & control), Humans, Levodopa (adverse effects), Neural Pathways (drug effects), Neural Pathways (metabolism), Neural Pathways (physiopathology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Receptors, Dopamine (drug effects), Receptors, Dopamine (metabolism).
MESH :
- chemical , adverse effects : Levodopa.
- chemical , drug effects : Receptors, Dopamine.
- chemical , metabolism : Dopamine, Receptors, Dopamine.
- drug effects : Brain, Neural Pathways.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- metabolism : Brain, Neural Pathways, Parkinson Disease.
- physiopathology : Brain, Dyskinesia, Drug-Induced, Neural Pathways, Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- Animals, Disease Models, Animal, Humans.

PubMed: 12442663

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001464
to stream PubMed, to step Curation: 001464
to stream PubMed, to step Checkpoint: 001464

Links to Exploration step

pubmed:12442663

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.</title>
<author><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A" last="Hadj Tahar">A. Hadj Tahar</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ, Institut Universitaire de Gériatrie de Montreal, Montreal, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ, Institut Universitaire de Gériatrie de Montreal, Montreal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R" last="Grondin">R. Grondin</name>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L" last="Grégoire">L. Grégoire</name>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F" last="Calon">F. Calon</name>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P J" last="Bédard">P J Bédard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12442663</idno>
<idno type="pmid">12442663</idno>
<idno type="wicri:Area/PubMed/Corpus">001464</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001464</idno>
<idno type="wicri:Area/PubMed/Curation">001464</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001464</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001464</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001464</idno>
<idno type="wicri:Area/Ncbi/Merge">000260</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.</title>
<author><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A" last="Hadj Tahar">A. Hadj Tahar</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ, Institut Universitaire de Gériatrie de Montreal, Montreal, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ, Institut Universitaire de Gériatrie de Montreal, Montreal, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R" last="Grondin">R. Grondin</name>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L" last="Grégoire">L. Grégoire</name>
</author>
<author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F" last="Calon">F. Calon</name>
</author>
<author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P J" last="Bédard">P J Bédard</name>
</author>
</analytic>
<series><title level="j">Advances in neurology</title>
<idno type="ISSN">0091-3952</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Brain (drug effects)</term>
<term>Brain (metabolism)</term>
<term>Brain (physiopathology)</term>
<term>Disease Models, Animal</term>
<term>Dopamine (metabolism)</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (physiopathology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Neural Pathways (drug effects)</term>
<term>Neural Pathways (metabolism)</term>
<term>Neural Pathways (physiopathology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Receptors, Dopamine (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
<term>Neural Pathways</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12442663</PMID>
<DateCreated><Year>2002</Year>
<Month>11</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted><Year>2003</Year>
<Month>01</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-3952</ISSN>
<JournalIssue CitedMedium="Print"><Volume>91</Volume>
<PubDate><Year>2003</Year>
</PubDate>
</JournalIssue>
<Title>Advances in neurology</Title>
<ISOAbbreviation>Adv Neurol</ISOAbbreviation>
</Journal>
<ArticleTitle>New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.</ArticleTitle>
<Pagination><MedlinePgn>51-64</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hadj Tahar</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Unité de Recherche en Neuroscience, Centre de Recherche du CHUQ, Institut Universitaire de Gériatrie de Montreal, Montreal, Quebec, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grondin</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grégoire</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Calon</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Di Paolo</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bédard</LastName>
<ForeName>P J</ForeName>
<Initials>PJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Adv Neurol</MedlineTA>
<NlmUniqueID>0367524</NlmUniqueID>
<ISSNLinking>0091-3952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>127</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2003</Year>
<Month>1</Month>
<Day>8</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">12442663</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><noCountry><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P J" last="Bédard">P J Bédard</name>
<name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F" last="Calon">F. Calon</name>
<name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T" last="Di Paolo">T. Di Paolo</name>
<name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L" last="Grégoire">L. Grégoire</name>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R" last="Grondin">R. Grondin</name>
</noCountry>
<country name="Canada"><noRegion><name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A" last="Hadj Tahar">A. Hadj Tahar</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000260 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:12442663
   |texte=   New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:12442663" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki